An RCT of Metformin Vs Orlistat in Obese Anovulatory Women
Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
This study aims to investigate the role of the weight reduction agent, Orlistat compared to
the Metformin for the management of women who are obese and do not ovulate or have difficulty
conceiving. Patients will receive either one of these medications and will be monitored at
regular intervals with hormone blood tests and ultrasound scans in order to study the effect
of the medications on the reproductive functions. Patients will receive the medications for
three months and the study will end if the patient becomes pregnant. The study also aims to
investigate the dose of metformin that should be used as there is no consensus to date
regarding the optimum dosage for this drug